Captopril-induced Bone Marrow Suppression in Two Cardiac Patients with Trisomy 21

Overview

Journal Pediatr Cardiol

Specialties Cardiology & Vascular Diseases
Pediatrics

Date 1993 Oct 1

PMID 8255797

Authors

M M Gleason

J S Roloff

S E Cyran

H S Weber

B G Baylen

J L Myers

Affiliations

Soon will be listed here.

Abstract

Neutropenia is an infrequent complication following administration of the angiotensin-converting enzyme (ACE) inhibitor, captopril. Most reports have been in adult patients, with rare reports in the pediatric population. We report two cases of neutropenia following captopril use in cardiac patients with trisomy 21. As this was not seen in patients without Down's syndrome, we postulate that patients with trisomy 21 have bone marrow which is "at risk" for suppression, and, thus warrant close evaluation while on such medications.

References

Schneeweiss A . Cardiovascular drugs in children. II. Angiotensin-converting enzyme inhibitors in pediatric patients. Pediatr Cardiol. 1990; 11(4):199-207. DOI: 10.1007/BF02238367. View

Weber M . Safety issues during antihypertensive treatment with angiotensin converting enzyme inhibitors. Am J Med. 1988; 84(4A):16-23. DOI: 10.1016/0002-9343(88)90465-2. View

Robison L, Nesbit Jr M, Sather H, Level C, Shahidi N, Kennedy A . Down syndrome and acute leukemia in children: a 10-year retrospective survey from Childrens Cancer Study Group. J Pediatr. 1984; 105(2):235-42. DOI: 10.1016/s0022-3476(84)80119-5. View

. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. The Captopril-Digoxin Multicenter Research Group. JAMA. 1988; 259(4):539-44. View

Hanukoglu A, Meytes D, Fried A, Rosen N, Shacked N . Fatal aplastic anemia in a child with Down's syndrome. Acta Paediatr Scand. 1987; 76(3):539-43. DOI: 10.1111/j.1651-2227.1987.tb10515.x. View

BENDIG L, Temesvari A . Indications and effects of captopril therapy in childhood. Acta Physiol Hung. 1988; 72 Suppl:121-9. View

Pantazis C, McKie V, Sabio H, DAVIS P, Allsbrook W . Down's syndrome and acute myelofibrosis. Time study of DNA content during the progression to leukemia. Cancer. 1988; 61(11):2239-43. DOI: 10.1002/1097-0142(19880601)61:11<2239::aid-cncr2820611118>3.0.co;2-5. View

Cooper R . Captopril-associated neutropenia. Who is at risk?. Arch Intern Med. 1983; 143(4):659-60. View

Mirkin B, Newman T . Efficacy and safety of captopril in the treatment of severe childhood hypertension: report of the International Collaborative Study Group. Pediatrics. 1985; 75(6):1091-100. View

10.

ODea R, Mirkin B, Alward C, Sinaiko A . Treatment of neonatal hypertension with captopril. J Pediatr. 1988; 113(2):403-6. DOI: 10.1016/s0022-3476(88)80292-0. View

11.

Edwards I, Coulter D, BEASLEY D, MacIntosh D . Captopril: 4 years of post marketing surveillance of all patients in New Zealand. Br J Clin Pharmacol. 1987; 23(5):529-36. PMC: 1386188. DOI: 10.1111/j.1365-2125.1987.tb03088.x. View

12.

Ganick D . Hematological changes in Down's syndrome. Crit Rev Oncol Hematol. 1986; 6(1):55-69. DOI: 10.1016/s1040-8428(86)80047-6. View

13.

Montigny M, DAVIGNON A, Fouron J, Biron P, Fournier A, Elie R . Captopril in infants for congestive heart failure secondary to a large ventricular left-to-right shunt. Am J Cardiol. 1989; 63(9):631-3. DOI: 10.1016/0002-9149(89)90915-6. View